Cholesterol and triglycerides is the main area connected here, and any felt benefit should be read together with the human evidence base.
The 57.4 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the B tier remains conservative.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Pain and headache. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Cardiovascular outcomes. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Cognition and focus. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Symptoms or adverse events reported in studies of this ingredient without another active ingredient.
These studies reported a negative change, reduced absorption, or another caution when substances were used together. They do not predict an individual outcome.
Paper IDs and full lists are private. Only study types and summaries are shown.
The risk of myopathy was increased by adding ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe), particularly in Chinese patients whose myopathy rates on simvastsatin were higher.
Fibrates reduce major coronary events and increase HDL-C levels without significant toxicity, and niacin has a more potent effect on HDL- C levels, whereas data on cardiovascular event rate reduction are limited.
Following a vegan diet may result in deficiencies in micronutrients (vitamin B12, zinc, calcium and selenium) which should not be disregarded, however, low micro- and macronutrient intakes are not always associated with health impairments.
In randomized controlled trials, triglyceride lowering is associated with lower risk of major vascular events, even after adjusting for LDL-C lowering, although the effect is attenuated when REDUCE-IT is excluded.
available literature data on the neuroprotective role of niacin and its derivatives are overviewed, especially focusing especially on its involvement in neurodegenerative diseases (Alzheimer’s, Parkinson's, and Huntington's diseases), as well as in other neuro
Conclusive evidence for the benefit of any supplement across all dietary backgrounds (including deficiency and sufficiency) was not demonstrated; therefore, any benefits seen must be balanced against possible risks.